Pfizer (NYSE:PFE) - Stock Price, News & Analysis

PFE Stock Overview

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

PFE fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	0/6
Past Performance	3/6
Financial Health	4/6
Dividends	5/6

Rewards

Trading at 66.7% below our estimate of its fair value

Pays a reliable dividend of 4.88%

Trading at good value compared to peers and industry

Risk Analysis

Earnings are forecast to decline by an average of 6.4% per year for the next 3 years

Pfizer Inc. Competitors

Merck

NYSE:MRK

US$272.3b

Bristol-Myers Squibb

NYSE:BMY

US$122.8b

Johnson & Johnson

NYSE:JNJ

US$392.3b

Zoetis

NYSE:ZTS

US$83.5b

Price History & Performance

Summary of all time highs, changes and price drops for Pfizer
Historical stock prices
Current Share Price	US$33.62
52 Week High	US$54.93
52 Week Low	US$33.44
Beta	0.55
1 Month Change	-9.16%
3 Month Change	-13.19%
1 Year Change	-23.45%
3 Year Change	-6.61%
5 Year Change	-23.03%
Change since IPO	1,036.45%

Pfizer: The Floor To This Decline Remains To Be Seen

Sep 02

Pfizer: Searching For A Bottom

Aug 24

Recent updates

Shareholder Returns

	PFE	US Pharmaceuticals	US Market
7D	-1.3%	-2.1%	-1.5%
1Y	-23.5%	15.1%	13.8%

Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.

Return vs Market: PFE underperformed the US Market which returned 13.8% over the past year.

Price Volatility

Is PFE's price volatile compared to industry and market?
PFE volatility
PFE Average Weekly Movement	2.6%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	5.6%
10% most volatile stocks in US Market	14.3%
10% least volatile stocks in US Market	2.5%

Stable Share Price: PFE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: PFE's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1849	83,000	Albert Bourla	https://www.pfizer.com

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands.

Pfizer Inc. Fundamentals Summary

How do Pfizer's earnings and revenue compare to its market cap?
PFE fundamental statistics
Market Cap	US$189.82b
Earnings (TTM)	US$21.49b
Revenue (TTM)	US$77.94b

8.8x

P/E Ratio

2.4x

P/S Ratio

Is PFE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
PFE income statement (TTM)
Revenue	US$77.94b
Cost of Revenue	US$23.52b
Gross Profit	US$54.42b
Other Expenses	US$32.93b
Earnings	US$21.49b

Last Reported Earnings

Jul 02, 2023

Next Earnings Date

Oct 31, 2023

Earnings per share (EPS)	3.81
Gross Margin	69.82%
Net Profit Margin	27.58%
Debt/Equity Ratio	66.1%

How did PFE perform over the long term?

See historical performance and comparison

Dividends

4.9%

Current Dividend Yield

42%

Payout Ratio

PFE Stock Overview

Rewards

Risk Analysis

Pfizer Inc. Competitors

NYSE:MRK

US$272.3b

NYSE:BMY

US$122.8b

NYSE:JNJ

US$392.3b

NYSE:ZTS

US$83.5b

Price History & Performance

Recent News & Updates

Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. (NYSE:PFE).

Pfizer Inc. to Report Q3, 2023 Results on Oct 31, 2023

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Pfizer: The Floor To This Decline Remains To Be Seen

Pyxis Oncology, Inc. (NasdaqGS:PYXS) completed the acquisition of Apexigen, Inc. (NasdaqCM:APGN) from entities associated with Pfizer Inc. (NYSE:PFE), Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.

Pfizer: Searching For A Bottom

Recent updates

Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. (NYSE:PFE).

Pfizer Inc. to Report Q3, 2023 Results on Oct 31, 2023

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Pfizer: The Floor To This Decline Remains To Be Seen

Pyxis Oncology, Inc. (NasdaqGS:PYXS) completed the acquisition of Apexigen, Inc. (NasdaqCM:APGN) from entities associated with Pfizer Inc. (NYSE:PFE), Lincoln Park Capital, LLC, managed by Laurion Capital Management LP, Bayer World Investments B.V. and others.

Pfizer: Searching For A Bottom

U.S. FDA Approves ABRYSVO, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age

Pfizer Stock: The Right Time To Buy Now (Technical Analysis)

Pfizer Inc. ELREXFIO Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma

Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave

Pfizer Inc. Provides Earnings Guidance for the Fiscal Year 2023

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Second quarter 2023 earnings released: EPS: US$0.41 (vs US$1.77 in 2Q 2022)

Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. (NYSE:PFE) for $1 billion.

Pfizer: Significant Plunge, Offering Exceptional Buying Opportunity

Pfizer Inc. Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate

Upcoming dividend of US$0.41 per share at 4.5% yield

Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.41

Pfizer: A 4.5% Dividend Yield Is A Gift

Pfizer: A Worthwhile Dividend Play At A Cheap Valuation

FDA Approves Pfizer’s Ngenla, A Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

Pfizer: Come For The Dividend - Stay For The Dividend

Pfizer Inc. Announces the U.S. Food and Drug Administration Accepts it’s Biologics License Application (BLA) for Fidanacogene Elaparvovec for the Treatment of Adults with Hemophilia B

Pfizer Inc. Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Melitus

Pfizer's (NYSE:PFE) Dividend Will Be $0.41

FDA Approves Pfizer's LITfulO (Ritlecitinib) for Adults and Adolescents with Severe Alopecia Areata

Pfizer Declares Third-Quarter Dividend 2023, Payable September 5, 2023

Pfizer Declares Third-Quarter Dividend 2023, Payable September 5, 2023

Shareholder Returns

Price Volatility

About the Company

Pfizer Inc. Fundamentals Summary

8.8x

2.4x

Earnings & Revenue

Dividends

4.9%

42%